Scheme 1.
Schematic representation of the protocol of the in vivo experiments performed on CT26 tumor-bearing BALB/c mice treated with ruthenium(II) complexes and oxaliplatin.
Figure 1.
The tumor volume per group through days of experiment.
Figure 2.
Survival rate of healthy mice and tumor-bearing mice after the administration of Ru(II) complexes and oxaliplatin.
Figure 3.
Body mass of healthy (A) and tumor-bearing mice (B) before and after treatment with Ru(II) complexes and oxaliplatin. The data are expressed as mean ± SD and were analysed by Student’s t test, * p < 0.05.
Figure 4.
The relative mass of isolated organs of healthy mice (A) and tumor-bearing mice (B) after treatment with Ru(II) complexes and oxaliplatin. The data are expressed as mean ± SD and were analysed by Student’s t test, * p < 0.05.
Figure 5.
Concentration of urea and creatinine in the serum of healthy (A, B) and tumor-bearing mice (C, D) after treatment with Ru(II) complexes and oxaliplatin. The data are expressed as mean ± SD and were analysed by Student’s t test, * p < 0.05.
Figure 6.
Concentration of transaminases (ALT and AST) in the serum of healthy (A, B) and tumor-bearing mice (C, D) after treatment with Ru(II) complexes and oxaliplatin. The data are expressed as mean ± SD and were analysed by Student’s t test, * p < 0.05.
Figure 7.
Histological examination. Representative hematoxylin and eosin staining of (A) tumor sections, (B) lungs, (C) heart, (D) kidney and (E) liver tissue of healty and CT26-tumor bearing mice treated with 5 mg/kg of Ru-1, Ru-2, oxaliplatin or saline (magnification at ×100).
Figure 8.
Values of (A) TBARS, (B) GSH, (C) SOD and (D) CAT in the homogenate of tumor, heart, liver, lungs and kidney tissues. The data are expressed as mean ± SD and were analysed by Student’s t тест, p<0.05, * saline treated cells vs. cells treated with Ru-1, Ru-2 or oxaliplatin; # Ru-1 vs. Ru-2; § Ru-1 vs. OX; ¶ Ru-2 vs. OX.